If you or a family member takes a prescription heart failure medication called Corlanor, check your medicine cabinet today. Nearly one million bottles of the drug — also known by its generic name ivabradine — have been recalled nationwide after an unexpected foreign substance was discovered on the surface of some tablets.
Amgen, Inc., the California-based pharmaceutical manufacturer that produces Corlanor, initiated a voluntary nationwide recall effective June 4, 2026, after quality inspections identified unexpected foreign matter on the exterior coating of tablets in a reserve sample from one of the affected production lots. The recalled bottles were manufactured in Italy and distributed across the United States.
The U.S. Food and Drug Administration has classified this as a Class II recall, meaning the agency has determined that the foreign substance represents a low probability of causing serious adverse health consequences, but that some exposure could result in temporary or medically reversible harm.
Why This Matters
Corlanor is not a widely discussed medication, but it is prescribed to a specific and medically vulnerable patient population: adults with chronic heart failure and a resting heart rate at or above 70 beats per minute who are already taking a maximally tolerated dose of a beta-blocker. The drug is also used in children as young as 6 months old with stable heart failure caused by an enlarged heart (dilated cardiomyopathy).
These patients typically cannot simply stop taking their medication. Abrupt discontinuation of heart failure medications can trigger worsening symptoms, hospitalization, or dangerous changes in heart rhythm. This makes the recall more complicated than a straightforward consumer product alert — patients need guidance before acting.
What We Know So Far
According to the FDA's enforcement report and multiple pharmacy board alerts:
- Recalled quantity : At least 934,577 bottles of 5 mg Corlanor (ivabradine) tablets
- Packaging formats affected : 14-tablet bottles and 60-tablet bottles
- Additional affected product : An undisclosed quantity of 7.5 mg Corlanor tablets in 60-tablet bottles
- Recall initiation date : June 4, 2026
- Manufacturing origin : Italy
- Distribution period : October 28, 2021 through December 30, 2025
- Expiration dates of affected lots : July 2026 through December 2028
- Recall classification : FDA Class II (low probability of serious adverse consequences)
- Patient complaints : None reported as of the recall initiation date
A California State Board of Pharmacy alert noted that the foreign matter was localized on the exterior tablet surface — specifically on the coating — rather than within the tablet itself. Amgen confirmed that the foreign material was identified during inspection of a reserve sample and that the substance represents "a low potential health risk to patients,"though some tablets may not meet internal quality standards for appearance.
The same recall also covers bottles of Sensipar (cinacalcet hydrochloride), an unrelated Amgen product used in chronic kidney disease patients. That recall involves 30 mg, 60 mg, and 90 mg Sensipar tablets in 30-count bottles.
Where the Risk Is Highest
Because Corlanor is a prescription-only medication dispensed directly to patients through retail and specialty pharmacies, the affected bottles could be in medicine cabinets across all 50 states. The distribution window spans more than four years, from October 2021 through December 2025, which means patients who have been taking Corlanor consistently for an extended period may have received multiple consecutive bottles from recalled lots.
Patients at the highest risk for serious complications from this recall are those who attempt to stop taking their medication without medical guidance. For heart failure patients, the risks of suddenly stopping a prescribed heart rate-controlling drug without physician oversight can include rapid heart rate, worsening shortness of breath, and increased risk of hospitalization.
What Doctors and Experts Say
An Amgen spokesperson confirmed to multiple news outlets that the foreign matter was identified in a "small number of units" and emphasized the precautionary nature of the recall. "While Amgen has determined that the presence of the foreign matter represents a low potential health risk to patients, some tablets may not meet internal quality standards for appearance," the company statement said, as reported by PEOPLE via MedPath.
The Cleveland Clinic notes in its patient resources that ivabradine works by decreasing heart rate, which reduces the amount of work the heart must perform — making it particularly important for patients with chronically elevated resting heart rates who cannot tolerate higher beta-blocker doses.
Physicians treating patients on Corlanor have emphasized that patients should not stop taking the medication based on the recall alone. Instead, the appropriate first step is to contact a pharmacist or prescriber to check the specific lot number on the bottle against the FDA's published recall list.
What the Evidence Shows — and What It Does Not
The FDA's Class II classification reflects the agency's assessment that the foreign matter found on tablet surfaces is unlikely to cause serious harm, but may pose a low risk of temporary or reversible adverse effects if ingested.
The recall notice does not identify the specific nature of the foreign substance, referring to it only as "unexpected foreign matter" located on the exterior coating. No patient injuries or complaints related to the recalled lots had been reported to Amgen or the FDA as of the recall initiation date.
Corlanor's underlying efficacy and safety profile are well-established. The drug's FDA approval in April 2015 was based largely on data from the SHIFT trial, which randomized more than 6,500 heart failure patients to ivabradine or placebo. The trial demonstrated a significant reduction in the combined endpoint of cardiovascular death and hospitalization for worsening heart failure. The recall does not affect the approval status of ivabradine, and generic versions of the drug are available from multiple suppliers, including from manufacturers not involved in this specific recall.
Who Faces the Greatest Risk?
The patients most affected by this recall are:
- Adults with chronic heart failure currently prescribed Corlanor 5 mg tablets in 14- or 60-tablet bottles from lots manufactured in Italy between October 2021 and December 2025
- Children aged 6 months and older prescribed Corlanor for stable dilated cardiomyopathy (an enlarged heart causing heart failure)
- Patients taking 7.5 mg Corlanor tablets in 60-count bottles from affected lots
- Patients who would be at medical risk if they discontinued the medication abruptly without physician guidance
Symptoms and Warning Signs to Watch For
If you have taken tablets from a recalled lot and experience any of the following, contact your prescriber or seek medical attention:
- Unusual changes in heart rate or rhythm
- Increased shortness of breath
- New or worsening swelling in legs or ankles
- Chest discomfort
- Nausea or vomiting not otherwise explained
- Any visible foreign material in your medication
Even if you experience no symptoms, it is still appropriate to contact your pharmacist to verify your lot number and discuss whether a replacement supply is indicated.
What You Can Do Now
- Check your bottle immediately. Locate the lot number and expiration date on your Corlanor bottle. Cross-reference these against the recalled lot numbers listed in the FDA enforcement report .
- Contact your pharmacist first. Your pharmacy can identify whether your specific prescription was filled from an affected lot and assist with obtaining a replacement supply — typically without an additional charge during an active recall.
- Do not stop taking Corlanor without speaking with your prescriber. This is critical for heart failure patients. Stopping a heart rate medication abruptly can cause dangerous cardiovascular changes.
- Call Amgen's Medical Information line if you have questions about the recall: 1-800-77-AMGEN.
- Report adverse events. If you believe you have experienced a health problem related to this product, report it to the FDA's MedWatch program at fda.gov/safety/medwatch .
Cost and Access: What Patients Should Know
Corlanor has been discontinued by Amgen as a branded product, but the active ingredient — ivabradine — remains available from multiple generic manufacturers not affected by this recall. Patients whose current supply is from a recalled lot should ask their pharmacist about switching to a generic supplier while replacement branded or generic stock is arranged.
Most pharmacies will replace recalled medication at no cost to the patient. Patients without insurance who need assistance affording replacement ivabradine can ask their pharmacist about generic pricing programs through GoodRx or similar discount platforms, where generic ivabradine may be available at significantly reduced cost.
What Happens Next
Amgen and the FDA have not set a public timeline for completing the recall process or for issuing a public close-out report. Active recalls of this scale — nearly one million affected units — typically remain open for several months while distributors, wholesalers, and pharmacies complete returns and destruction of affected product.
The FDA Enforcement Report will be updated as the recall progresses. MedicalDaily will follow up when the recall is formally closed or if new information emerges about the nature of the foreign substance.
The Bottom Line
If you take Corlanor or know someone who does, the most important first step is to check the lot number on the bottle against the FDA's published recall list and to contact a pharmacist before stopping the medication. The FDA's Class II classification indicates the risk is likely low, but with nearly a million bottles in circulation across a multi-year distribution window, the potential for unreported patient exposure is significant. This is a precautionary recall that requires patient awareness and medical coordination, not panic.
